Personalized health and the coronavirus vaccines—Do individual genetics matter?

Vaccines represent preventative interventions amenable to immunogenetic prediction of how human variability will influence their safety and efficacy. The genetic polymorphism among individuals within any population can render possible that the immunity elicited by a vaccine is variable in length and...

Full description

Saved in:
Bibliographic Details
Published in:BioEssays 2021-09, Vol.43 (9), p.e2100087-n/a
Main Authors: Valdés‐Fernández, Bianca N., Duconge, Jorge, Espino, Ana M., Ruaño, Gualberto
Format: Article
Language:English
Subjects:
Antigens
Chemokine receptors
Coronaviruses
COVID-19
Customization
Dendritic cells
Deoxyribonucleic acid
DNA
Gene polymorphism
Genetic diversity
Genetic variance
Genetics
HLA
human polymorphism
Immune system
Immunogenetics
Immunoglobulins
Interferon
Interferon receptors
Interleukins
Lymphocytes
Macrophages
Major histocompatibility complex
mRNA
Natural killer cells
Polymorphism
Problems & Paradigms
reactogenicity
Receptors
Severe acute respiratory syndrome coronavirus 2
Vaccines
Viral diseases
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vaccines represent preventative interventions amenable to immunogenetic prediction of how human variability will influence their safety and efficacy. The genetic polymorphism among individuals within any population can render possible that the immunity elicited by a vaccine is variable in length and strength. The same immune challenge (virus and/or vaccine) could provoke partial, complete or even failed protection for some individuals treated under the same conditions. We review genetic variants and mechanistic relationships among chemokines, chemokine receptors, interleukins, interferons, interferon receptors, toll‐like receptors, histocompatibility antigens, various immunoglobulins and major histocompatibility complex antigens. These are the targets for variation among macrophages, dendritic cells, natural killer cells, T‐ and B‐lymphocytes, and complement. The technology platforms (mRNA, viral vectors, proteins) utilized to produce vaccines against SARS‐CoV‐2 infections may each trigger genetically distinct immune reactogenic profiles. With DNA biobanking and immunoprofiling of recipients, global COVID‐19 vaccinations could launch a new era of personalized healthcare. SARS‐CoV‐2 vaccines are amenable to immunogenetic response prediction. The same challenge (virus, vaccine) could provoke complete, partial, or failed protection and variable reactogenicity among individuals. We review genetic variation in immunity and HLA. Production platforms (mRNA, vectors, and proteins) may elicit genetically distinct reactogenic profiles. Vaccine recipient bioprofiling advances personalized health.
ISSN:0265-9247
1521-1878
DOI:10.1002/bies.202100087